Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 575-588

  Chaturvedi, Mayank ^a   Molino, Yves ^b   Sreedhar, Bojja ^c   Khrestchatisky, Michel ^d   Kaczmarek, Leszek ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b Indian Institute of Chemical Technology ^*

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d Mediterranée University   (France)

Author keywords

BBB penetration; Brain delivery; Drug delivery; PLGA nanoparticles; Protein delivery; RBCEC culture; Sustained release

Indexed keywords

DRUG CARRIER; MATRIX METALLOPROTEINASE; NANOPARTICLE; POLYGLACTIN; POLYSORBATE 80; SOLVENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; DELAYED RELEASE FORMULATION; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYSORBATE; SURFACTANT; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN CELL CULTURE; CONTROLLED STUDY; DRUG BINDING; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; ENZYME INHIBITION; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOEMULSION; NONHUMAN; RAT; ANIMAL; CELL CULTURE; CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; ENDOTHELIUM CELL; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; LACTIC ACID; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; POLYGLYCOLIC ACID; POLYSORBATES; RATS; SURFACE-ACTIVE AGENTS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84892889053     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S54750     Document Type: Article

References (34)

1. Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev. 2012;33(3):457-516.
2. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209.
3. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3): 329-347.
4. Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm. 2010;74(2):157-163.
5. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9in patients with Alzheimer's disease. Neurochem Int. 2003;43(3):191-196.
6. Sang QX, Muroski M, Roycik M, et al. Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008;9(1):34-46.
7. Rooprai H, McCormick D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res. 1997;17(6B):4151-4162.
8. Sharshar T, Durand MC, Lefaucheur JP, et al. MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome. Neurology. 2002;59(10):1649-1651.
9. Zhang H, Chang M, Hansen CN, Basso DM, Noble-Haeusslein LJ. Role of matrix metal proteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics. 2011;8(2):206-220.
10. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238(1-2):53-56.
11. Yin P, Yang L, Zhou HY, Sun RP. Matrix metalloproteinase-9may be a potential therapeutic target in epilepsy. Med. Hypotheses. 2011;76(2): 184-186.
12. Jourquin J, Tremblay E, Decanis N, et al. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci. 2003;18(6): 1507-1517.
13. Koistinaho M, Malm TM, Kettunen MI, et al. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005;25(4): 460-467.
14. Kaczmarek L. MMP-9inhibitors in the brain: can old bullets shoot new targets? Curr Pharm Des. 2012;19(6):1085-1089.
15. Chaturvedi M, Kaczmarek L. MMP-9inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol. Epub September 12, 2013.
16. Sa Y, Hao J, Samineni D, et al. Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats. Neurol Res. 2011;33(4):433-438.
17. Batra J, Robinson J, Mehner C, et al. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One. 2012;7(11):e50028.
18. Chaturvedi M, Figiel I, Sreedhar B, Kaczmarek L. Neuroprotection from tissue inhibitor of metalloproteinase-1 and its nanoparticles. Neurochem Int. 2012;61(7):1065-1071.
19. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemiareperfusion injury. FASEB J. 2009;23(5):1384-1395.
20. Panyam J, Dali MM, Sahoo SK, et al. Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nanoand microparticles. J Control Release. 2003;92(1-2):173-187.
21. Roux F, Durieu-Trautmann O, Chaverot N, et al. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol. 1994;159(1):101-113.
22. Roux FS, Mokni R, Hughes CC, Clouet PM, Lefauconnier JM, Bourre JM. Lipid synthesis by rat brain microvessel endothelial cells in tissue culture. J Neuropathol Exp Neurol. 1989;48(4):437-447.
23. Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol. 2005;25(1):41-57.
24. Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol. 2005;25(1):59-127.
25. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002;244(1-2):105-115.
26. Dey SK, Mandal B, Bhowmik M, Ghosh LK. Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy. Braz J Pharm Sci. 2009;45(3):585-591.
27. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3): 1377-1397.
28. Bilati U, Allémann E, Doelker E. Poly(D, L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion methodprocessing and formulation issues for enhanced entrapment efficiency. J Microencapsul. 2005;22(2):205-214.
29. Kreuter J. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J Microencapsul. 2013;30(1):49-54.
30. Rempe R, Cramer S, Hüwel S, Galla HJ. Transport of poly(n-butylcyanoacrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem Biophys Res Commun. 2011;406(1):64-69.
31. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm. 2008;70(2):627-632.
32. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65-81.
33. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004;4(5): 484-488.
34. Knapska E, Lioudyno V, Kiryk A, et al. Reward learning requires activity of matrix metalloproteinase-9in the central amygdala. J Neurosci. 2013;33(36):14591-14600.